BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication
(WorldNews Health)

BioMarin Provides 1.5 years of Clinical Data for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A at 59th American Society of Hematology (ASH) Annual Meeting Concurrent with NEJM Publication Valoctocogene Roxaparvovec Demonstrated Sustained Normal or Near Normal Factor VIII Levels in Severe Hemophilia A for Most Patients at Both Doses in Phase 1/2 Study Global GENEr8-1 (Phase 3) Study to Begin Before Year End, and Global GENEr8-2 (Phase 3) Study to Begin at the Start of 2018 SAN RAFAEL, Calif., Dec. 9, 2017/PRNewswire / -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today an update to its previously reported results of an open-label Phase 1/2 study of valoctocogene...